Vetoquinol SA
Open
BrancheGesundheitswesen
68.8 -1.71
Übersicht
Veränderung der Aktienkurses
24h
Min
67.7
Max
70.2
Einkommen | 7.2M 32M |
|---|---|
Verkäufe | 10M 268M |
KGV Branchendurchschnitt | 14.069 49.712 |
Dividendenrendite | 1.33 |
Gewinnspanne | 12.043 |
Angestellte | 2,422 |
EBITDA | 252M 301M |
Empfehlungen | Buy |
|---|---|
12-Monats-Prognose | +58.27% upside |
Dividendenrendite Branchendurchschnitt | 1.33% 2.36% |
|---|---|
Nächstes Ergebnis | 11. Sept. 2026 |
Marktkapitalisierung | -127M 808M |
|---|---|
Vorheriger Eröffnungskurs | 70.51 |
Vorheriger Schlusskurs | 68.8 |
Nachrichtenstimmung
By Acuity
50%
50%
166 / 342 Ranking in Healthcare
Vetoquinol SA Chart
Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.
Über Vetoquinol SA
Vetoquinol SA, a veterinary pharmaceutical company, designs, develops, and sells veterinary drugs and non-medicinal products in Europe, the Americas, and the Asia Pacific region. It provides products in the areas of mobility, pain, and inflammation; dermatology, hygiene, and care; anti-parasite; udder health; infectious diseases; reproduction; behavior management; internal medicine; and cardiology-nephrology for cattle, sheep, pigs, poultry, dogs, cats, and horses. The company was founded in 1933 and is headquartered in Lure, France. Vetoquinol SA is a subsidiary of Soparfin SCA.
